logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Immunotherapy and some other results from ESMO 2018

IMMUNOTHERAPY   The Checkpoint Inhibitors The most revered news was the discovery of the checkpoint proteins on the surface of the immune system cells. The checkpoint proteins ’ natural job is to put a break on the immune system cells...

Read More

October 24, 2018

0

Exelixis' and Daiichi Sankyo's Novel Antihypertensive Drug Minnebro® Hits the Japanese Market

Exelixis and Daiichi Sankyo launched their novel anitihypertension product Minnebro® in Japan Exelixis ( EXEL )   and   Daiichi Sankyo  ( DSNKY )  Limited informed that Daiichi has launched their novel antihypertension product Minnebro ®  (esaxerenone) tablets in Japan. Exelixis ...

Read More

May 13, 2019

0

Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

The FDA Approval of Regeneron's EYLEA Is Important The PANORAMA Trial of EYLEA for Diabetic Retinopathy The United States Food and Drug Administration (FDA) has approved Regeneron’s ( REGN ) product EYLEA® (aflibercept) Injection for all stages of diabetic retinopathy . This approval...

Read More

May 14, 2019

0

Prenatal gene editing has already been performed in laboratory animals

Although the tests are for the prevention of a life-threatening metabolic disorder, the prenatal animal testing may be offering the potential to treat many human congenital diseases before birth. The research, which comes from Children's Hospital of Philadelphia (CHOP) and...

Read More

October 26, 2018

0

Motif Bio Has Good News. Amicus Therapeutics Has a Series of Good News

MOTIF BIO Antibiotic Motif Bio’s (MTFB ) antibiotic drug  Iclaprim met the Phase 3 Revive-2 trial’s primary endpoints of non-inferiority against the current standard of care antibiotic, vancomycin in acute bacterial skin and skin structure infections (ABSSSI). The drug demonstrated a...

Read More

October 5, 2017

0

Another Late-Stage Firm with Impressive Technology and Promising Products

About Iovance Biotherapeutics Iovance Biotherapeutics ( IOVA ) is   a late-stage biotechnology company developing novel cancer immunotherapies based on its tumor-infiltrating lymphocyte (TIL) technology. Iovance announced promising updates from ongoing clinical trials in advanced cervical cancer and advanced melanoma...

Read More

May 16, 2019

0

The Medicines Company: Are Inclisiran's Clinical Trial Results Impressive?

The Medicines Company Are Inclisiran's Clinical Trial Results Impressive? Our answer is YES. The trial results came out with several, not just one, good news.  Inclisiran's Good News The first good news  came from the ORION-3 study, conducted by The...

Read More

May 21, 2019

0

About the Celyad/Horizon discovery agreement

Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc,  for the use of its shRNA technology to generate Celyad’s second non-gene-edited allogeneic platform. The encouragement came from data emanating from preclinical studies demonstrating the versatility of the shRNA...

Read More

November 1, 2018

0

Array BioPharma: Great News and a Learning Experience

Great News for Array BioPharma  Array BioPharma ( ARRY ) announced positive results from the interim analysis of the Phase 3 BEACON CRC trial. The trial evaluates the combination of: Braftovi ®  (encorafenib) , a BRAF inhibitor, Mektovi ®  (binimetinib)...

Read More

May 21, 2019

0

About Exelixis

Exelixis (EXEL) provided an update that testified to its solid fundamentals, the growth of its approved products’ sales, the professionalism and seriousness of its management. Revenues: Exelixis’ total quarter revenues were  $225.4 million vs. $152.5 million  for the comparable period...

Read More

November 2, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 60
  • 61
  • 62
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy